Supplier · public contract awards

Gilead Sciences GmbH public contracts.

Gilead Sciences GmbH has won 78 public contracts between 2017 and 2026 from 11 public buyers in Germany. Its most frequent buyer is GWQ ServicePlus AG (18 awards). Outside TED, published values total €429,000 across 2 awards. 40 awards were published on TED; the median contract size is about €210,000 (2 contracts with a value).

Start bidding All awards in Germany

78Contracts won

11Public buyers

1Country

Jul 2026Latest award

Latest contracts won

Németország – Gyógyszerészeti termékek – Vereinbarung nach § 130c Abs. 1 SGB V für das Arzneimittel Epclusa mit der Wirkstoffkombination Sofosbuvir/Ve

Awarded by AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen · Germany

28 Jul 2026Awarded

Németország – Gyógyszerészeti termékek – Arzneimittelrabattvereinbarung gemäß § 130c Abs. 1 SGB V zu der Wirkstofffixkombination Sofosbuvir/Velpatasvi

Awarded by AOK Baden-Württemberg · Germany

15 Jul 2026Awarded

Abschluss eines nicht-exklusiven Rabattvertrages gemäß § 130c Abs. 1 SGB V zwischen der IKK classic und der Gilead Sciences GmbH zu Vemlidy(R)

Awarded by IKK classic · Germany

9 Jun 2022Awarded

Abschluss eines nicht-exklusiven Rabattvertrages gemäß § 130a Abs. 8 und § 130c Abs. 1 SGB V zwischen der IKK classic und der GILEAD Sciences GmbH zu

Awarded by IKK classic · Germany

6 Nov 2020Awarded

Abschluss eines nicht-exklusiven Rabattvertrages gemäß § 130c Abs. 1 SGB V zu Descovy(R) (Wirkstoffe: Emtricitabin und Tenofoviralafenamid, ATC-Code:

Awarded by IKK classic · Germany

15 Jul 2020Awarded

Abschluss eines nicht-exklusiven Rabattvertrages gemäß § 130a Abs. 8 SGB zu Yescarta(R) (Wirkstoff: Axicabtagen-Ciloleucel)

Awarded by IKK classic · Germany

27 May 2019Awarded

Ex-Ante-Transparenzbekanntmachung Vertrag gem. § 130c SGB V Harvoni und Epclusa

Awarded by AOK Bayern – Die Gesundheitskasse · Germany

17 Oct 2018Awarded

Abschluss eines nicht-exklusiven Rabattvertrages nach § 130c Abs. 1 SGB V zur Wirkstoffkombination Sofosbuvir | Velpatasvir

Awarded by actimonda Krankenkasse · Germany

2 Jul 2018Awarded

Abschluss eines nicht-exklusiven Rabattvertrages nach § 130c Abs. 1 SGB V zur Wirkstoffkombination Ledipasvir | Sofosbuvir

Awarded by actimonda Krankenkasse · Germany

2 Jul 2018Awarded

Abschluss nicht exklusiver Rabattverträge nach § 130a Abs. 8 SGB V zu Arzneimitteln mit der Wirkstoffkombination Emtricitabin, Tenofovirdisoproxil, Ef

Awarded by AOK - Rheinland-Pfalz/Saarland – Die Gesundheitskasse · Germany

2 Mar 2018Awarded

Contracts won by year

from the published records

201710

20188

20192

20204

20222

20262

Published value, by currency (feeds other than TED)

EUR · 2 valued

€429,000

Typical contract size on TED

EUR · median of 2 contracts

€210,000

From published award records. Suppliers are matched by legal name; a company with a different legal name in another country (a national subsidiary, for example) has its own page. Each currency is shown on its own and never converted. TED values are often framework ceilings, so TED awards show a median contract size, never a total.

Bid with askTender

Bidding against Gilead Sciences GmbH?

askTender reads every open tender against your company profile — eligibility, the gaps, and the documents you need — and can prepare the entire bid.

Start bidding See open tenders